BLFS BioLife Solutions Inc

H.C. Wainwright has reiterated its Buy rating on BioLife Solutions (NASDAQ:BLFS), setting a price target of $32.00, which suggests approximately 29% upside from the current price. The firm adjusted its financial statements for 2024 and 2025 to exclude revenue from its divested evo cold chain logistics subsidiary, aligning with management's FY2025 revenue guidance of $95.0-96.0 million. This re-affirmation follows BioLife Solutions' strong Q3 2025 earnings and the opening of the Aby J. Mathew Center for Biopreservation Excellence.

H.C. Wainwright has reiterated its Buy rating on BioLife Solutions (NASDAQ:BLFS) with a price target of $32.00, aligning with the broader analyst consensus. The firm adjusted its financials to exclude revenue from a divested subsidiary and projects FY2025 revenue of $95.8 million, with FY2026 revenue projected at $112.6 million. This follows recent positive earnings results and the opening of a new biopreservation excellence center.

Amy Duross, a Director at BioLife Solutions Inc (BLFS), sold 2,000 shares of the company on December 15, 2025, reducing her holdings to 18,687 shares. This transaction follows 95 insider sells and no buys over the past year for BLFS. The stock was trading at $24.6, indicating it is "Fairly Valued" based on its GF Value.

BioLife Solutions' (NASDAQ:BLFS) CFO, Troy Wichterman, sold 30,000 shares of the company stock on December 4th, for approximately $771,600. This insider sale occurred amid a modest downtrend in the share price of the bioproduction tools provider for cell and gene therapy. The transaction value was based on a weighted average sale price of $25.72 according to the SEC Form 4 filing.

BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman sold 30,000 shares of company stock for $771,600 in early December 2025. This transaction, occurring at an average price of $25.72 per share, leaves Wichterman with 152,769 shares. The sale comes amidst positive company news, including strong Q3 2025 earnings and the opening of a new biopreservation facility.

BioLife Solutions, Inc. (NASDAQ:BLFS) currently has a high price-to-sales (P/S) ratio of 12.2x, significantly above the industry average, which suggests it might be overvalued. However, this high P/S ratio is likely justified by its strong recent revenue growth of 88% and an anticipated 18% annual revenue increase over the next three years, outperforming the industry forecast of 6.6%. Investors appear confident in the company's future prospects, leading to the elevated P/S ratio.